suppl masthead
(Source: Seminars in Hematology)
Source: Seminars in Hematology - September 30, 2016 Category: Hematology Source Type: research
Table of Contents
(Source: Seminars in Hematology)
Source: Seminars in Hematology - September 30, 2016 Category: Hematology Source Type: research
Alternative donor allogeneic transplants: Introduction
Allogeneic hematopoietic stem cell transplantation is now a 60-year-old lady, who has aged with grace, becoming more refined and sophisticated, ever evolving to better fit with the needs of a growing cancer population. Since its inception, one of the defining major limitations of this approach has been a lack of donor availability. In the last 15 years, we observed a remarkable number of advances in the procedure, chief amongst which include new possibilities for the use of alternative donors, which have dramatically broadened the application of this life-saving procedure. (Source: Seminars in Hematology)
Source: Seminars in Hematology - August 29, 2016 Category: Hematology Authors: Richard Childs, Didier Blaise Source Type: research
Selecting the best haploidentical donor
The substantial evidence of the safety of human leukocyte antigen (HLA)-haploidentical (haplo) blood or marrow transplantation (BMT) has led to its increasing utilization. When prioritizing HLA-matched grafts, patients frequently have few or no donors from whom to choose. However, a given patient may have multiple suitable haplo donors. Therefore factors other than HLA-match become critical for selecting the best donor. We recommend a donor selection algorithm based on the donor-specific antibodies, ABO match, donor age, donor sex, and cytomegalovirus (CMV) serostatus match. (Source: Seminars in Hematology)
Source: Seminars in Hematology - August 14, 2016 Category: Hematology Authors: Shannon R. McCurdy, Ephraim J. Fuchs Source Type: research
Selecting the best haploidenitcal donor
The substantial evidence of the safety of human leukocyte antigen (HLA)-haploidentical (haplo) blood or marrow transplantation (BMT) has led to its increasing utilization. When prioritizing HLA-matched grafts, patients frequently have few or no donors from whom to choose. However, a given patient may have multiple suitable haplo donors. Therefore factors other than HLA-match become critical for selecting the best donor. We recommend a donor selection algorithm based on the donor-specific antibodies, ABO match, donor age, donor sex, and cytomegalovirus serostatus match. (Source: Seminars in Hematology)
Source: Seminars in Hematology - August 14, 2016 Category: Hematology Authors: Shannon R. McCurdy, Ephraim J. Fuchs Source Type: research
Umbilical cord blood cells from unrelated donor as an alternative source of hematopoietic stem cells for transplantation in children and adults
Umbilical cord blood (CB)is an alternative source of hematopoietic stem cells (HSC) for patients requiring allogeneic HSC transplantation but lacking a suitable HLA-matched donor. Using CB has many advantages, including lower HLA-matching requirements, increased donor availability and low rates of graft-versus-host disease. Furthermore, with over 630,000 cryopreserved volunteer CB units currently stored in international CB banks worldwide, CB is rapidly available for those patients requiring urgent transplantation. (Source: Seminars in Hematology)
Source: Seminars in Hematology - August 14, 2016 Category: Hematology Authors: Vanderson Rocha Source Type: research
Matched unrelated donor transplants —state of the art in the 21st century
Hematopoietic stem cell transplantation (HSCT) is the therapy of choice in many hematological malignant and non-malignant diseases by using human leukocyte antigen (HLA)-matched siblings as stem cell source but only one third of the patients will have HLA-matched siblings. Hence, physicians rely on the availability of matched unrelated donors (URD). The possibility of finding a matched URD is now more than 70% due to continuous expansion of URD registries around the world. The use of URD in adult patients is steadily increasing and in the last 8 years has superseded the numbers of matched sibling donor transplants and has ...
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Syed Y. Altaf, Jane F. Apperley, Eduardo Olavarria Source Type: research
Haploidentical cord transplantation —the best of both worlds
Haploidentical (haplo)-cord transplantation combines infusion of an umbilical cord blood (UCB) unit with CD34-selected cells usually from human leukocyte antigen (HLA) mismatched donors. Initial rapid count recovery from the haplo-hematopoietic progenitors, is gradually replaced by durable engraftment from UCB progenitors. UCB grafts used for haplo-cord are smaller, but better matched than those required for single or double UCB stem cell transplant (SCT). More than 200 patients with hematological malignancies have been transplanted. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Koen van Besien, Richard Childs Source Type: research
Haploidentical transplants using ex vivo T-cell depletion
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Massimo F. Martelli, Franco Aversa Source Type: research
Haplo transplants using ex vivo T cell depletion
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Massimo F. Martelli, Franco Aversa Source Type: research
Mismatched Unrelated Donor Transplantation
There are now over 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although an HLA-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mismatching may be considered. Significant advances in clinical and basic research have been instrumental in furthering the understanding of donor-recipient HLA mismatches that are better tolerated than other mismatches. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Effie W. Petersdorf Source Type: research
Haplo Cord Transplantation – The Best of Both Worlds
Haplo-cord transplantation combines infusion of an umbilical cord blood unit with CD34 selected cells usually from HLA mismatched related donors. Initial rapid count recovery results from the haplo-identical hematopoietic progenitors, which in the majority of cases are gradually replaced by durable engraftment from umbilical cord blood progenitors. UCB grafts used for haplo-cord tend to be smaller, but better matched than those required for single or double UCB SCT. Over 200 patients with hematological malignancies have been transplanted at two institutions. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Koen van Besien, Richard Childs Source Type: research
Matched unrelated donor transplants – State of the art in the 21st century
Haematopoietic stem cell transplantation (HSCT) is the therapy of choice in many haematological malignant and non-malignant diseases by using human leucocyte antigen (HLA)-matched siblings as stem cell source but only one third of the patients will have HLA-matched siblings. Hence, physicians rely on the availability of matched unrelated donors (URD). The possibility of finding a matched URD is now more than 70% due continuous expansion of URD registries around the world. The use of URD in adult patients is steadily increasing and in the last 8 years, has superseded the numbers of matched sibling donor transplants and has ...
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Syed Y. Altaf, Jane F. Apperley, Eduardo Olavarria Source Type: research
Haplo transplants using ex vivo T cell depletion
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Massimo F. Martelli, Franco Aversa Source Type: research
Mismatched Unrelated Donor Transplantation
There are now over 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although an HLA-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mismatching may be considered. Significant advances in clinical and basic research have been instrumental in furthering the understanding of donor-recipient HLA mismatches that are better tolerated than other mismatches. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 24, 2016 Category: Hematology Authors: Effie W. Petersdorf Source Type: research
